{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:37:56Z","timestamp":1786995476135,"version":"build-2736575974"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.pbb.2011.09.006","type":"journal-article","created":{"date-parts":[[2011,10,3]],"date-time":"2011-10-03T10:53:31Z","timestamp":1317639211000},"page":"398-403","source":"Crossref","is-referenced-by-count":31,"title":["Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents"],"prefix":"10.1016","volume":"100","author":[{"given":"Nandkishor R.","family":"Kotagale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh G.","family":"Taksande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paresh J.","family":"Wadhwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh W.","family":"Palhade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin M.","family":"Mendhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh Y.","family":"Gawande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin N.","family":"Hadole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrabhan T.","family":"Chopde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.pbb.2011.09.006_bb0005","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1038\/npp.2010.106","article-title":"Ventral striatal noradrenergic mechanisms contribute to sensorimotor gating deficits induced by amphetamine","volume":"35","author":"Alsene","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2011.09.006_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0306-9877(85)90114-8","article-title":"The side effects of antimalarial drugs indicate a polyamine involvement in both schizophrenia and depression","volume":"18","author":"Andrews","year":"1985","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.pbb.2011.09.006_bb0015","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1210\/en.2002-0147","article-title":"Nitric oxide inhibits prolactin secretion in pituitary cells downstream of voltage-gated calcium influx","volume":"144","author":"Andric","year":"2003","journal-title":"Endocrinol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1196\/annals.1304.014","article-title":"Is agmatine an endogenous anxiolytic\/anti-depressant agent?","volume":"1009","author":"Aricioglu","year":"2003","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.pbb.2011.09.006_bb0025","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0024-3205(97)00801-1","article-title":"Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats","volume":"61","author":"Aricioglu-Kartal","year":"1997","journal-title":"Life Sci"},{"issue":"4","key":"10.1016\/j.pbb.2011.09.006_bb0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0773.1982.tb01032.x","article-title":"Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade","volume":"51","author":"Arnt","year":"1982","journal-title":"Acta Pharmacol Toxicol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0035","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bbr.2009.05.015","article-title":"Differences among conventional, atypical and novel putative D2\/5-HT1A antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys","volume":"203","author":"Auclair","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2011.09.006_bb0040","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1254\/jjp.69.285","article-title":"Selective inhibition of inducible nitric oxide synthase by agmatine","volume":"69","author":"Auguet","year":"1995","journal-title":"Jpn J Pharmacol"},{"issue":"6548","key":"10.1016\/j.pbb.2011.09.006_bb0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/377424a0","article-title":"Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors","volume":"377","author":"Baik","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2011.09.006_bb0050","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.npp.1300940","article-title":"Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties","volume":"31","author":"Bardin","year":"2006","journal-title":"Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.pbb.2011.09.006_bb0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/FBP.0b013e3280ae6c96","article-title":"Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2\/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics","volume":"18","author":"Bardin","year":"2007","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0091-3057(02)01079-1","article-title":"An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine","volume":"74","author":"Bence","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2011.09.006_bb0065","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1210\/edrv-6-4-564","article-title":"Dopamine: a prolactin inhibiting hormone","volume":"6","author":"Ben-Jonathan","year":"1985","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pbb.2011.09.006_bb0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.schres.2005.05.019","article-title":"The many faces of nitric oxide in schizophrenia. A review","volume":"78","author":"Bernstein","year":"2005","journal-title":"Schizophrenia Res"},{"key":"10.1016\/j.pbb.2011.09.006_bb0075","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0028-3908(99)00041-6","article-title":"On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia","volume":"38","author":"Black","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2011.09.006_bb0080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00174869","article-title":"Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine","volume":"338","author":"Broekkamp","year":"1988","journal-title":"Arch Pharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0006-8993(88)91584-3","article-title":"Quinolinic acid lesions of rat striatum abolish D1- and D2-dopamine receptor-mediated catalepsy","volume":"450","author":"Calderon","year":"1988","journal-title":"Brain Res"},{"key":"10.1016\/j.pbb.2011.09.006_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0014-2999(78)90251-0","article-title":"Climbing behavior induced by apomorphine in mice: a potential model for the detection of neuroleptic activity","volume":"50","author":"Costall","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0014-2999(74)90201-5","article-title":"Mesolimbic involvement with behavioural effects indicating antipsychotic activity","volume":"27","author":"Costall","year":"1974","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2006.01.051","article-title":"Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release","volume":"535","author":"Cosi","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"16","key":"10.1016\/j.pbb.2011.09.006_bb0105","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1523\/JNEUROSCI.0370-11.2011","article-title":"Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1\/M4 preferring muscarinic receptor agonist xanomeline","volume":"31","author":"Dencker","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.pbb.2011.09.006_bb0110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjp.0707159","article-title":"F15063, a compound with D2\/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (II) activity in models of positive symptoms of schizophrenia","volume":"151","author":"Depoortere","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1073\/pnas.92.1.170","article-title":"Role of nitric oxide in control of prolactin release by the adenohypophysis","volume":"92","author":"Duvilanski","year":"1995","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.pbb.2011.09.006_bb0120","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2011.09.006_bb0125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s11064-005-6865-9","article-title":"Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity","volume":"30","author":"Gilad","year":"2005","journal-title":"Neurochem Res"},{"issue":"4","key":"10.1016\/j.pbb.2011.09.006_bb0130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(94)00256-3","article-title":"Polyamines and their metabolizing enzymes in human frontal cortex and hippocampus: preliminary measurements in affective disorders","volume":"38","author":"Gilad","year":"1995","journal-title":"Biol Psychiatry"},{"issue":"11","key":"10.1016\/j.pbb.2011.09.006_bb0135","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2165\/00023210-200721110-00002","article-title":"Agmatine metabolic pathway and spectrum of activity in brain","volume":"21","author":"Halaris","year":"2007","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.pbb.2011.09.006_bb0140","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02246184","article-title":"Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability","volume":"120","author":"Hoffman","year":"1995","journal-title":"Psychopharmacol"},{"issue":"1","key":"10.1016\/j.pbb.2011.09.006_bb0145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF02245458","article-title":"Inhibition of neuronal nitric oxide synthase by antipsychotic drugs","volume":"114","author":"Hu","year":"1994","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0150","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0028-3908(88)90134-7","article-title":"8-Hydroxy-2-(di-N-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis","volume":"27","author":"Invernizzi","year":"1988","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2011.09.006_bb0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/10401230309085668","article-title":"Clozapine: a clinical review of adverse effects and management","volume":"15","author":"Iqbal","year":"2003","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.pbb.2011.09.006_bb0160","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.bbr.2010.11.016","article-title":"Nitric oxide synthase inhibitors improve prepulse inhibition responses of Wistar rats","volume":"217","author":"Issy","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2011.09.006_bb0165","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.bbr.2009.08.003","article-title":"Nitric oxide modulation of methylphenidate-induced disruption of prepulse inhibition in Swiss mice","volume":"205","author":"Issy","year":"2009","journal-title":"Behav Brain Res"},{"issue":"10","key":"10.1016\/j.pbb.2011.09.006_bb0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0024-3205(95)02037-J","article-title":"The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study","volume":"57","author":"Kapur","year":"1995","journal-title":"Life Sci"},{"key":"10.1016\/j.pbb.2011.09.006_bb0175","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.57.6.553","article-title":"A positron emission tomography study of quetiapine in schizophrenia","volume":"57","author":"Kapur","year":"2000","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2011.09.006_bb0180","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00213-002-1006-5","article-title":"The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents","volume":"161","author":"Khisti","year":"2002","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2004.09.042","article-title":"The neuronal selective nitric oxide synthase inhibitor, N N-propyl-l-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice","volume":"503","author":"Klamer","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0190","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00213-004-1901-z","article-title":"Habituation of acoustic startle is disrupted by psychotomimetic drugs: differential dependence on dopaminergic and nitric oxide modulatory mechanisms","volume":"176","author":"Klamer","year":"2004","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2005.02.005","article-title":"Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats","volume":"49","author":"Kleven","year":"2005","journal-title":"Neuropharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0200","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbr.2010.04.049","article-title":"Repeated agmatine treatment attenuates nicotine sensitization in mice: modulation by \u03b12-adrenoceptors","volume":"213","author":"Kotagale","year":"2010","journal-title":"Behav Brain Res"},{"issue":"1","key":"10.1016\/j.pbb.2011.09.006_bb0205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0166-4328(02)00326-1","article-title":"Agmatine induces anxiolysis in the elevated plus maze task in adult rats","volume":"141","author":"Lavinsky","year":"2003","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2011.09.006_bb0210","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pbb.2011.09.006_bb0215","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.pbb.2010.08.007","article-title":"Agmatine inhibits morphine-induced memory impairment in the mouse step-down inhibitory avoidance task","volume":"97","author":"Lu","year":"2010","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.pbb.2011.09.006_bb0220","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/da.10026","article-title":"Prepulse inhibition deficits in patients with panic disorder","volume":"15","author":"Ludewig","year":"2002","journal-title":"Depress Anxiety"},{"issue":"1","key":"10.1016\/j.pbb.2011.09.006_bb0225","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0230","first-page":"281","article-title":"The pharmacology of olanzapine and other new antipsychotic agents","volume":"2","author":"Moore","year":"1993","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.pbb.2011.09.006_bb0235","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/sj.bjp.0702679","article-title":"Protection by imidazoline drugs and agmatine of glutamate induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor","volume":"127","author":"Olmos","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0240","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0024-3205(03)00297-2","article-title":"Agmatine attenuates neuropathic pain in rats: possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum","volume":"73","author":"Onal","year":"2004","journal-title":"Life Sci"},{"key":"10.1016\/j.pbb.2011.09.006_bb0375","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2011.03.010","article-title":"Agmatine blocks ethanol-induced locomotor hyperactivity in male mice","volume":"659","author":"Ozden","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0250","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejphar.2008.06.022","article-title":"Agmatine attenuates the disruptive effects of phencyclidine on prepulse inhibition","volume":"590","author":"Palsson","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.pbb.2011.09.006_bb0255","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0920-9964(94)90049-3","article-title":"Role of polyamines in the membrane pathology of schizophrenia. A study using fibroblasts from schizophrenic patients and normal controls","volume":"13","author":"Ramchand","year":"1994","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pbb.2011.09.006_bb0260","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.mp.4001779","article-title":"A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function","volume":"11","author":"Reif","year":"2006","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pbb.2011.09.006_bb0265","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0165-6147(00)01460-7","article-title":"Is agmatine a novel neurotransmitter in brain?","volume":"21","author":"Reis","year":"2000","journal-title":"Trends in Pharmacological Sci"},{"key":"10.1016\/j.pbb.2011.09.006_bb0270","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1054-3589(08)61020-0","article-title":"New approaches to the drug treatment of schizophrenia","volume":"32","author":"Reynolds","year":"1995","journal-title":"Adv Pharmacol"},{"issue":"2","key":"10.1016\/j.pbb.2011.09.006_bb0275","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0306-9877(83)90059-2","article-title":"A central role for the polyamines in the aetiology of schizophrenia","volume":"11","author":"Richardson-Andrews","year":"1983","journal-title":"Med Hypotheses"},{"issue":"1","key":"10.1016\/j.pbb.2011.09.006_bb0280","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1523\/JNEUROSCI.1970-10.2011","article-title":"Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: relevance for schizophrenia","volume":"31","author":"Rotaru","year":"2011","journal-title":"J Neurosci"},{"issue":"5755","key":"10.1016\/j.pbb.2011.09.006_bb0285","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/284472a0","article-title":"Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors","volume":"284","author":"Sanberg","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2011.09.006_bb0380","first-page":"261","article-title":"Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4","volume":"7","author":"Seeman","year":"1992","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0295","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/jnnp.58.2.192","article-title":"Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease","volume":"58","author":"Swerdlow","year":"1995","journal-title":"J Neurol Neurosurgery Psychiatry"},{"issue":"4","key":"10.1016\/j.pbb.2011.09.006_bb0300","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/0006-3223(93)90300-3","article-title":"A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder","volume":"33","author":"Swerdlow","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2011.09.006_bb0305","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2010.03.058","article-title":"Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats","volume":"637","author":"Taksande","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"10.1016\/j.pbb.2011.09.006_bb0310","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00005053-199810000-00002","article-title":"Information processing in schizophrenia and bipolar disorder: a discriminant analysis","volume":"186","author":"Tam","year":"1998","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.pbb.2011.09.006_bb0315","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/sj.npp.1300460","article-title":"Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents","volume":"29","author":"Ugale","year":"2004","journal-title":"Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.pbb.2011.09.006_bb0320","first-page":"175","article-title":"New pharmacological approaches to the treatment of schizophrenia","volume":"20","author":"Uzbay","year":"2009","journal-title":"Turk Psikiyatri Derg"},{"key":"10.1016\/j.pbb.2011.09.006_bb0325","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/0269881109102533","article-title":"Agmatine disrupts prepulse inhibition of acoustic startle reflex in rats","volume":"24","author":"Uzbay","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0330","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejphar.2009.12.020","article-title":"Sex-related effects of agmatine on caffeine-induced locomotor activity in Swiss Webster mice","volume":"630","author":"Uzbay","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0335","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0166-4328(99)00127-8","article-title":"Effect of agmatine on ethanol withdrawal syndrome in rats","volume":"107","author":"Uzbay","year":"2000","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2011.09.006_bb0340","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF02251281","article-title":"Potency mismatches for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine","volume":"110","author":"Wadenberg","year":"1993","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0345","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.euroneuro.2007.04.001","article-title":"Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats","volume":"17","author":"Wei","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2011.09.006_bb0350","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0022-3565(24)37988-1","article-title":"Agmatine selectively blocks the N-methyl-d-aspartate subclass of glutamate receptor channels in rat hippocampal neurons","volume":"288","author":"Yang","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2011.09.006_bb0355","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000098367","article-title":"Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia","volume":"16","author":"Yilmaz","year":"2007","journal-title":"Med Princ Pract"},{"issue":"6","key":"10.1016\/j.pbb.2011.09.006_bb0360","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1460-9568.2008.06104.x","article-title":"Exogenous agmatine has neuroprotective effects against restraint-induced structural changes in the rat brain","volume":"27","author":"Zhu","year":"2008","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pbb.2011.09.006_bb0365","first-page":"387","article-title":"Agmatine produces antidepressant-like effects in two models of depression in mice","volume":"13","author":"Zomkowski","year":"2002","journal-title":"Neuroscience Report"},{"key":"10.1016\/j.pbb.2011.09.006_bb0370","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.brainres.2004.07.041","article-title":"Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test","volume":"1023","author":"Zomkowski","year":"2004","journal-title":"Brain Res"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305711003133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305711003133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:16:31Z","timestamp":1741763791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305711003133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0091305711003133"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2011.09.006","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}